

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
10 November 2022 (10.11.2022)



(10) International Publication Number
WO 2022/235663 A1

(51) International Patent Classification:

A61K 39/12 (2006.01) A61K 39/39 (2006.01)
C07K 14/165 (2006.01) A61P 31/14 (2006.01)
A61K 39/215 (2006.01)

(21) International Application Number:

PCT/US2022/027465

(22) International Filing Date:

03 May 2022 (03.05.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/184,727	05 May 2021 (05.05.2021)	US
63/193,356	26 May 2021 (26.05.2021)	US
63/255,685	14 October 2021 (14.10.2021)	US
63/332,537	19 April 2022 (19.04.2022)	US

(71) Applicant: **NOVAVAX, INC.** [US/US]; 21 Firstfield Road, Gaithersburg, Maryland 20878 (US).


(72) Inventors; and

(71) Applicants: **PATEL, Nita** [US/US]; c/o Novavax, Inc., 21 Firstfield Road, Gaithersburg, Maryland 20878 (US). **ZHOU, Bin** [CN/US]; c/o Novavax, Inc., 21 Firstfield Road, Gaithersburg, Maryland 20878 (US). **GUEBRE-XABIER, Mimi** [US/US]; c/o Novavax, Inc., 21 Firstfield Road, Gaithersburg, Maryland 20878 (US). **TIAN, Jing-Hui** [US/US]; c/o Novavax, Inc., 21 Firstfield Road, Gaithersburg, Maryland 20878 (US). **PORTNOFF, Alyse D.** [US/US]; c/o Novavax, Inc., 21 Firstfield Road, Gaithersburg, Maryland 20878 (US). **MASSARE, Michael J.** [US/US]; c/o Novavax, Inc., 21 Firstfield Road, Gaithersburg, Maryland 20878 (US). **SHINDE, Vivek** [US/US]; c/o Novavax, Inc., 21 Firstfield Road, Gaithersburg, Maryland 20878 (US). **FRIES, Louis** [US/US]; c/o Novavax, Inc., 21 Firstfield Road, Gaithersburg, Maryland 20878 (US). **SMITH, Gale** [US/US]; c/o Novavax, Inc., 21 Firstfield Road, Gaithersburg, Maryland 20878 (US).

(74) Agent: **BROWN, Fraser D.** et al.; Cooley LLP, 1299 Pennsylvania Ave., Suite 700, Washington, District of Columbia 20004 (US).

(54) Title: CORONAVIRUS AND INFLUENZA COMPOSITIONS AND METHODS FOR USING THEM

Fig. 13B



(57) Abstract: Disclosed herein are compositions and methods for inducing immune responses against both influenza and coronavirus-es. Provided herein are compositions and methods of using the same, wherein the compositions comprise: (a) a coronavirus S (CoV S) glycoprotein in the form of a detergent-core nanoparticle, wherein the detergent is a non-ionic detergent; (b) at least three hemagglutinin (HA) glycoproteins, wherein each HA glycoprotein is from a different influenza strain; and (c) a pharmaceutically acceptable buffer.

[Continued on next page]

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))